Investors & Funding
VenatoRx has been awarded multiple grants and contracts from the NIH, including 5 SBIRs, an R01 grant, and a contract. The company has also received funding from the Wellcome Trust and private investors.
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands‐on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit versantventures.com
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from startups to publicly traded companies, and across all life science sectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 142 life science companies, leading to 64 IPOs and 41 mergers and acquisitions. For more information, please visit abingworth.com
Foresite Capital provides capital and support to help companies with transformative products and services become healthcare leaders. Through close collaboration with visionary entrepreneurs and a relentless focus on innovation and building value, Foresite Capital aims to dramatically enhance patient care. Since Foresite Capital’s inception in 2011, the firm’s strategy has been to offer complete capital solutions to help build category‐defining companies across therapeutics, devices, diagnostics and healthcare services. For more information, please visit foresitecapital.com
CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator) is the world’s largest public-private partnership devoted to early stage antibacterial R&D. Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X will spend up to $455 million from 2017-2021 to support innovative products from ‘hit-to-lead’ stage through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is a charitable global public-private partnership led by Boston University. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit carb-x.org and follow us on Twitter @CARB_X
The Wellcome Trust
The Wellcome Trust is a global charity dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
VenatoRx has received an investment from the Wellcome Trust for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.” For more information, please visit wellcome.ac.uk
National Institute of Allergy and Infectious Diseases (NIAID)
NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.
NIAID advances the understanding, diagnosis, and treatment of many of the world’s most intractable and widespread diseases. Key research areas include newly emerging and re-emerging infectious diseases such as tuberculosis and influenza, HIV/AIDS, biodefense, and immune-mediated diseases including asthma and allergy.
Responding to a Broad Agency Announcement (BAA-NIAID-DMID-NIHAI2012149) solicitation titled “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases,” VenatoRx has been selected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. VenatoRx has also received multiple research grant awards from NIAID to address infections related to biodefense and public health, including an R01 and multiple SBIR grants. For more information, please visit niaid.nih.gov